Harnessing the collective wisdom of the world’s medical thought leaders.
Converting it into actionable insights for all stakeholders in disease management - Pharma, Payers, Clinicians, Regulators, Investors and most of all, Patients.
BOLT’s Though Leader Panels bring together the knowledge and expertise of the world’s best clinicians and researchers. Each Panelist is internationally recognized for their contributions to understanding and curing diseases.
Resonance
There are a million consulting groups serving industry and the investment community. None are quite like us. We’ll give you unbiased thoughts and ideas from outside the echo chamber.
Why We’re All In The Business...
Ultimately we are about helping patients and their families to live better lives. In our Patient Forum you’ll find our favorite links, and medical information for the public
Welcome to BOLT International
Latest News:
Gastroenterology Thought Leader Panel #13 2011-12 is available for immediate download. Follow the “Buy Now” link at the top of this page!
In Gastroenterology Thought Leader Panel #10, conducted in April 2010, we asked six internationally recognized experts in the treatment of inflammatory bowel disease to engage with us in a thought exercise with the aim of ranking the most medically valuable initiatives in the developmental pipeline. Each was asked to “buy” five agents that they were most looking forward to having available in the next few years – their “Fantasy Formulary”. In Gastroenterology TLP #13 2011-12, we rerun and expand this thought experiment.
The Panel was most interested in opining on recent clinical data related to three groups of therapeutics: integrin/adhesion/MAdCAM, IL-23/IL-23 and (new to the survey in late 2011 vs early 2010) JAK. These three classes accounted for 53% of the Panel’s value allocation. They predict the likelihood of approvals and use in the treatment of inflammatory bowel disease. A second tier of mechanisms, accounting for 24% of the value to the Panel included a variety of probiotics/fetal transplants (helminthes, bacterial IL10 delivery), stem cell transplants, and IL6 inhibitors.
Other mechanisms discussed in this report include TNF, steroids, CCR9, PI3k, folate, IL-17, GMCSF, S1P, and IP10.
Drugs mentioned in this report include:
Company
Generic
Brand
Abbott (Eisai)
adalimumab
Humira (with Eisai)
Ablynx
Ablynx / Pfizer
ALX-0061
ATN-103
Anterogen
ANTG-ASC-203
Ardeypharm
E. coli nissle 1917
Avaxia
AVX-470; polyclonal bovine anti-TNF
Bayer-Schering
sargramostin; GMCSF
Leukine
Bristol-Myers Squibb
MDX-1100
Celgene
PDA001
ChemoCentryx / GlaxoSmithKline
CCX-282 B
Traficet-EN
Elan / Biogen
natalizumab
Tysabri
Emergent / Pfizer
X1 TNFR x Anti-IL6
Falk
Salix / Dr. Falk
LT-02 + Mutaflor
budesonide
Budenofalk
Ferring
FE-301
Genentech / Roche
rhuMAb-b7; RG7413
J&J / Janssen / Merck / Essex
infliximab
ustekinumab; CNTO-1275
golimumab
Remicade
Stelara
Simponi
Lilly
INCB-28050 / LY3009104
Merck (Schering-Plough)
SCH-900222
Millennium / Takeda
vedolizumab (MLN-02)
Neovacs
TNF Kinoid
Novartis
secukinumab; AIN-457
fingolimod
Gilenia
Osiris Therapeutics
mesenchymal stem cell
Prochymal
Pfizer
Pfizer/Athersys
tofacitinib; CP-690550
PF-00547659
PF-0528541
PF-042369
MultiStem
Santaris
budesonide
Entocort MMX
Toray
TRK-170
UCB
certolizumab
Cimzia
Vertex
VX-509
Looking to access BOLT’s Syndicated Thought Leader Panel reports? Over the past 15 years BOLT International has moderated over 4,000 Thought Leader interviews across a wide range of therapeutic categories. These are summarized and analyzed in BOLT’s Thought Leader Panels; many of which are available to the public. To date there are over 300 reports available through our partner, MedPredict, at www.medpredict.com. You can also purchase the actual interview transcripts, by year or by therapeutic category. Contact me by email to discuss pricing (jeff@boltinternational.com). We have recently installed a “buy now” feature on this website. There you will see our most current releases, available for instant purchase by credit card. While we will be retro-stocking our storefront, if you don’t see what you want, ask. A note to patients: we discount our pricing to bona fide patients on a case-by-case basis – especially if our information will help you and your physician improve your care. Seriously, we’ll need a note from your doctor!
Competence – BOLT International’s core competence is the integration of healthcare and pharmaceutical information sets into insightful commercial strategies. Our comprehensive understanding of healthcare product lifecycles – from biotech start-ups through research and clinical development, and onto global marketing, pricing and reimbursement strategies – permits us to develop concise, actionable recommendations.
Experience – BOLT’s leadership position in Healthcare Competitive Intelligence is derived from years of professional experience in both the science and the business of healthcare. BOLT’s principals know the industry, the firms, the markets, the politics and the technologies. This experience base – enhanced with BOLT’s THOUGHT LEADER physician panels, and our secondary information gathering and analysis techniques – permits us to provide actionable recommendations to a wide-variety of healthcare industry clients.
Knowledge – BOLT’s THOUGHT LEADER panels give us proprietary access to decision makers (physicians, patients, payers and regulators) in numerous geographies. This in turn drives our understanding of key issues and development of winning strategies – Strategies that reflect a complete analysis of the events predictive of both the direction and the rate of change within the healthcare industry. As a result, you’ll implement sound decisions with the confidence that your actions are based on the most comprehensive competitive, technical and financial analyses available.
Attention – BOLT provides the attention to service and detail that can be missing when dealing with large, general competitive intelligence firms. Our ability to meet your timing needs and to deliver the quality of analysis you demand is unparalleled.
“I’ve engaged Jeff Berk and BOLT International on numerous projects, at four different companies, over almost 20 years. He has his finger on the pulse of the current developments in Pharma, Biotech and Healthcare. His vast network of Thought Leaders is the best I have found anywhere. The depth and breadth of his advice has been helpful in many strategic decisions. Whether I’m calling him for a large due diligence project, or a quick piece of advice, he always has something insightful to share and the data to back up his opinion.” - U.S.-based VP Business Development, Pharma.
